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The pp125 focal adhesion kinase (FAK) is involved in integrin-mediated cell signalling and overexpressed in a variety of solid tumours.
Focal adhesion kinase expression has been correlated to invasion and metastasis, but the data on breast cancer are inconclusive. We
analysed FAK mRNA, protein levels and expression patterns in primary breast cancer and normal breast tissue. FAK expression on
the functional protein level and mRNA was determined in 55 matched pairs of breast cancer and corresponding normal tissue by
Western blot, immunohistochemistry and RT–PCR. Using a score ranging from 0 to þ5 for Western blots, we determined in
normal breast tissue a score of 1.5170.84 (mean7standard deviation), which was strongly induced to 2.91 (71.22) in breast
cancers (Po0.001). Overall, 45 out of 55 tissue pairs (81.8%) showed this upregulation of FAK protein in tumours in comparison to
normal tissue. Immunohistochemistry confirmed these findings with a significant higher score for tumours vs physiological tissue
(1.070.63 vs 2.2770.91; P¼0.001). Interestingly, no overall significant difference in the mRNA levels (P¼0.359) was observed. In
conclusion, expression levels of the FAK protein are specifically upregulated in breast cancer in comparison to matched normal breast
tissue supporting its pivotal role in neoplastic signal transduction and representing a potential marker for malignant transformation.
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Neoplasia is characterised by abnormal cellular signalling due to
an induction of protein tyrosine kinases and overexpression of
other involved proteins like integrins (Hanahan and Weinberg,
2000; Hunter, 2000; Cruet-Hennequart et al, 2003). This phenom-
enon has implications for the initiation and progression of a
variety of human cancers including gynaecological malignancies
(Ullrich and Schlessinger, 1990; Hunter, 2000; Gabriel et al, 2002).
Besides receptor tyrosine kinases, pure cytoplasmic tyrosine
kinases are also involved in tumorigenesis and anchorage-
independent growth of cells. An early and crucial event in signal
transduction process in this regard is the phosphorylation of
protein tyrosine residues. A pertinent downstream target is pp125
focal adhesion kinase (FAK), which binds to the b1 integrin
subunit (Danker et al, 1998; Parsons, 2003). It represents a 125kDa
nonreceptor tyrosine kinase, which is ubiquitously expressed
throughout development, widely detectable in adult tissues and
specifically localised in focal adhesions, which represent contact
sites for extracellular matrix interactions. Focal adhesion kinase
holds a key position in the signal transduction network and is
phosphorylated in response to clustering of integrins, cell
spreading or formation of focal adhesions and acts as a scaffold
for the assembly of multiprotein signalling complexes (Zachary
and Rozengurt, 1992).
Functional FAK activities include cell cycle regulation and
apoptosis (Xu et al, 1996; Zhao et al, 1998; Beviglia et al, 2003).
Several studies confirmed a pivotal role of FAK in tumorigenesis
and metastasis with elevated expression levels in various human
malignancies (Owens et al, 1995; McCormack et al, 1997; Agochiya
et al, 1999; Judson et al, 1999; Oktay et al, 2003). These findings
were associated with enhanced cell migration (Cary et al, 1996)
and proliferation (Wang et al, 2000). In lung cancer, the induced
phosphorylation of pp125FAK was positively correlated to lymph
node metastasis (Imaizumi et al, 1997). The tumour biological
importance of FAK was confirmed by experiments targeting
pp125FAK with antisense oligonucleotides leading to an inhibition
of cell migration, invasion and proliferation as well as an induction
of apoptosis and enhanced sensitivity to campothecins (Hunger-
ford et al, 1996; Golubovskaya et al, 2002; Satoh et al, 2003).
So far there are only few, sometimes controversial reports lin-
king FAK to breast cancer (Glukhova et al, 1995; Cance et al, 2000;
Golubovskaya et al, 2002; Oktay et al, 2003; Satoh et al, 2003). Two
studies found an upregulation of FAK expression during tumo-
rigenesis from physiological tissue, via DCIS into invasive cancer
(Cance et al, 2000; Oktay et al, 2003). Their results were compro-
mised by the heterogeneity of tissue samples with benign specimen,
DCIS and invasive tumours from different patients as well as low
sample numbers. Two recently published large studies on 629 and
162 invasive breast cancers, respectively, found a correlation
between FAK expression and an aggressive tumour phenotype.
High FAK protein levels were associated with Her2/neu amplifica-
tion and high tumour grading by immunohistochemistry, but both
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sstudies did not focus on the transition from normal to malignant
breast tissue (Lark et al, 2005; Schmitz et al, 2005).
Our analysis focussed on the characterisation of pp125FAK
expression in matched pairs of normal and malignant breast
tissues from 55 individual patients on the mRNA as well as
functional protein level.
PATIENTS AND METHODS
Patients and tissues
Fresh frozen tumour and physiological tissue samples of 55
consecutive patients who had surgery for primary breast cancer at
the Department of Obstetrics and Gynaecology of Freiburg in 2003
were analysed. The patients had a mean age of 61 years. After
approval by the local ethics committee (No. 313/2002) and written
informed consent of each single patient, the removed tissue was
sent immediately to the local pathologist for frozen section
analysis. Tumour samples and corresponding physiological tissue
of the same patient were frozen in liquid nitrogen and stored at
 801C until further analysis.
Two specialised and well-trained breast pathologists performed
the characterisation of the tissue samples. The tumours were
classified according to the TNM System. For histological analysis,
tissue samples were fixed in 4% formalin and stained with
haematoxylin–eosin. Additional immunohistochemical analysis
was performed when necessary. The mean diameter of the tumours
was 28.8731.4mm (mean7standard deviation (s.d.)). Histological
type and tumour size were determined according to the WHO
criteria (WHO, 1981). We found 37 (67.3%) ductal invasive, 13
(23.6%) lobular invasive and five (9.1%) other types of invasive
breast cancers. Grading was assessed according to Elston and Ellis
(1991). Axillary lymph node status was obtained by sentinel lymph
node biopsy after radionuclid labelling or axillary dissection in
case of metastatic sentinel lymph nodes. Oestrogen and progester-
one receptor status was determined by immunohistochemistry.
The DAKO Hercept Testt (DakoCytomation, Glostrup, Denmark)
was used to assess the HER2/neu status. Detailed clinical data of
the patients are given in Table 1.
Protein isolation and Western blot
Total cellular protein was isolated from the inter- and phenol
phase from the initial homogenate after precipitation of the DNA
(0.3ml 100% of ethanol per 1ml of TRIzol) as described
previously. Briefly, proteins dissolved in the phenol–ethanol
supernatant were precipitated with isopropyl alcohol (1.5ml per
1ml TRIzol), pelleted (12000 g,4 1C, 10min) and washed three
times with 0.3 M guanidine hydrochloride in 95% ethanol. Finally,
the pellets were resuspended in 1% SDS solution and incubated at
501C for complete dissolution. Insoluble material was removed by
centrifugation (10000 g, 10min, 41C) and the supernatants were
stored at  801C until further analysis. For SDS–PAGE (10% gel),
20mg of total protein were applied per lane and separated. Proteins
were electroblotted onto a PVDF membrane (PolyScreen, NEN Life
Science, Boston, MA, USA) at 110V for 1.0h at 41C. Unspecific
binding sites of the membrane were blocked with 5% Blotto/PBST
prior to incubation with the specific monoclonal FAK antibody
(BD Biosciences, Franklin Lakes, USA) diluted 1:1250 in blocking
solution. Bound primary antibody was visualised using horse-
radish-peroxidase labelled secondary goat-anti-mouse-IgG-anti-
body (Pierce, Rockford, USA) diluted 1:5000 in conjunction with a
chemiluminescence detection system (Amersham Biosciences,
Buckinghamshire, UK). Protein loads were normalised against b-
actin and staining intensity was categorised by a visual score
ranging from 0 to þ5.
Immunohistochemistry
Formalin-fixed, paraffin-embedded slides of 12 randomly chosen
patients were soaked in Roticlear (Pure Science, Wellington, New
Zealand) and rehydrated in a graded alcohol series (100–50%). To
recover antigenicity we used the Antigen Retrieval System
(BioGenex, San Ramon, USA) once for 60min in an autoclave at
601C. Afterwards, the slides were washed in PBS. The primary
monoclonal antibody was specific for FAK (Clone No. 610087, BD
Transduction Laboratories, Franklin Lakes, USA). Sections were
incubated with the primary antibody diluted 1:500 in PBS for
60min at 371C. After rinsing in PBS sections were incubated for
another 30min with the link antibody, horseradish-peroxidase
labelled secondary goat-anti-mouse-IgG-antibody (Pierce, Rock-
ford, USA) diluted 1:500 in PBS. Afterwards the sections were
coated with DAB staining reagent for 10min at room temperature.
Sections were rinsed in PBS and counterstained with haematox-
ylin, rinsed in water, dehydrated in 100% ethanol and equilibrated
in xylol before mounting. The semiquantitative score ranged from
negative to weak and strong staining reaction, assessing only the
intensity (score 0 to þ3).
RNA isolation and RT–PCR
Tissues from 32 randomly chosen patients were minced on dry ice
before treatment with a tissue homogeniser (Polytron, Littau,
Switzerland) in Trizol solution (1ml per 100mg tissue, three times
10s; Gibco-BRL, Gaithersburg, MD, USA). After 5min of incuba-
tion at room temperature (RT), chloroform (0.2ml per 1ml of
Trizol) was added, the solution was shaken vigorously and
incubated (RT, 5min). After centrifugation (12000 g, 15min,
41C) total RNA was precipitated by addition of isopropyl alcohol to
the aqueous phase (0.5ml per 1ml of Trizol, 10min RT). The RNA
was pelleted by centrifugation (12000 g, 10min, 41C), washed
with 75% ethanol (1ml of ethanol per 1ml of TRIzol reagent used
for the initial homogenisation), recovered by centrifugation
(7500 g, 5min, 41C) and finally dissolved in RNAse-free water
and stored at  801C for further analysis.
In total, 5mg of RNA, as determined by optical densitometry,
were used for cDNA synthesis using M-MuLV reverse transcriptase
(Perkin-Elmer, Branchburg, NJ, USA) and oligo-dT primers. For
amplification of cDNA, primers specific for FAK and 18S as
control were used.
Primers were as follows:
FAK:
FAK S: 50-TTA GAC AAT TTG CCA ACC TT-30
FAK AS: 50-CAC CTT CTT TCT GAG GTC TG-30
18 S:
18S S: 50-AAC TCA CTG AGG ATG AGG TG-30
18S AS: 50-CAG ACA AGG CCT ACA GAC TT-30
Table 1 Clinical data of 55 breast cancer patients
No (%) Yes (%)
Age p50 years 13 (23.6) 42 (76.4)
Tumour diameter o20mm 29 (52.7) 26 (47.3)
Grading 1and 2 46 (83.6) 9 (16.4)
Her 2/neu score 3+ 46 (83.6) 9 (16.4)
Lymph node metastasis 37 (67.3) 18 (32.7)
Distant metastasis 49 (89.1) 6 (10.9)
Multilocal growth pattern 30 (54.5) 25 (45.5)
Lymphangiosis 39 (70.9) 16 (29.1)
Oestrogen receptor 15 (27.3) 40 (72.7)
Progesterone receptor 19 (34.5) 36 (65.5)
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respectively, dNTps, buffer and Taq polymerase in a total volume
of 50ml. Amplification was for 30 cycles consisting of denaturing at
941C (60s), annealing at 551C (30s) and extension at 721C (45s).
For visualisation of amplified cDNA, 10ml from each reaction
were submitted to electrophoresis on an agarose gel (2%).
PeqGOLD DNA Sizer XI or XII (Peqlab Biotech, Erlangen,
Germany) was used for size determination. Expected amplicon
sizes were 417bp for FAK and 305bp for 18S, respectively.
Statistical analysis
To allow a reliable statistical analysis in the given population, the
results of the clinical and histological examination were dichot-
omised according to Table 1. The percentage of amplified FAK
cDNA in correlation to the amplified 18S cDNA was used in the
RT–PCR analysis. The w
2 test was applied to analyse the relation
between the clinical and histological parameters and the test
results. T-test for paired samples compared mean values of the
tumour and normal tissue analysis. All P-values are two tailed. Any
P-value lower than 0.05 was considered to be statistically
significant. The analysis was performed with the SPSS Software
package version 13.0.
RESULTS
For this study, matched tissue pairs (n¼55) of invasive breast
cancer and corresponding physiological breast tissue of the same
patient were analysed for their pp125FAK protein expression by
Western blot analysis and immunohistochemistry as well as for
RNA expression levels by RT–PCR.
pp125 FAK protein concentration is increased in breast
cancer
To examine the expression profile of the pp125FAK on the
functional level, we analysed at first the matched tissue samples by
Western blot using the monoclonal antibody described above
(Figure 1). The additional bands ranging from 70 to 85kDa are
known to be caspase cleavage products and were previously
described (Gervais et al, 1998; van de Water et al, 1999; Mao et al,
2003) and do not compromise the value of the 125kDa band. The
mean score was 1.5170.84 in physiological tissue vs 2.9171.22 in
tumours; this difference was highly significant (Po0.001) (Fig-
ure 2).
In more detail, the analysis of the score distribution revealed
that 50 out of 55 normal tissue specimen (90.9%) were valued with
a score of 0 to þ2. Interestingly, score þ1 was given in 30 out of
55 probes or 54.5% of all physiological tissue specimen. Only five
(9.1%) samples were detected with a score of þ3o rþ5 (Table 2).
In contrast, invasive breast cancer displayed a strong FAK
expression. Score þ3t oþ5 was found in 33 out of 55 (60%)
specimen, with 17 out of 55 (30.9%) in the highest two score ranks
þ4 and þ5. Only seven out of 55 tumours (12.7%) got a score of
þ1 (Table 2).
In a further step we analysed the relation between the
histopathological and clinical parameters shown in Table 1 and
the pp125 FAK protein expression. The w
2 test revealed only a
significant positive correlation between pp125 FAK expression and
high tumour grading (P¼0.29), while all other parameters
including the Her2/neu status showed no significant correlation.
FAK protein expression is specifically upregulated in
breast cancer
The immunohistochemical analysis of pp125 FAK expression in
tumours vs corresponding and physiological breast tissue showed
comparable results like the Western blot analysis.
In the normal epithelial cells of the breast in general, a weak to
no expression was observed with a mean score of 1.070.63. In
invasive breast cancer we found a site-specific induction of pp125
FAK expression (mean score7s.d.: 2.2770.91) (Figure 2). This
difference was highly significant in the statistical analysis
(P¼0.001). The expression was mostly restricted to the membrane
of the epithelial cancer cells, and sometimes also present in a few
stromal cells (Figure 3A and B). In parallel to our Western blot
results, the matched pair analysis revealed in all but one of
examined tissue samples an induction of pp125 FAK expression in
tumours vs their corresponding physiological control.
12345 6+
123 456+
125 kDa
41.7 kDa
Figure 1 Induction of pp125 FAK expression in breast cancer. Matched
pairs of normal and malignant tissue specimen from the same patient were
analysed for their FAK expression by Western blot. Lane 1, tumour 1; lane
2, normal 1; lane 3, tumour 2; lane 4, normal 2; lane 5, tumour 3; lane 6,
normal 3; þ, positive control. pp 125 FAK corresponding to 125kDa, b-
actin corresponding to 41.7kDa as internal control.
IHC
tumour
IHC
normal
Western
blot tumour
Western 
blot normal
5
4
3
2
1
0
Figure 2 Box plot analysis of the Western blot score and immunohis-
tochemistry of pp125 FAK expression in the breast. Matched pairs of
normal and malignant breast tissue were analysed by Western blot with a
specific monoclonal FAK antibody. The bold black line represents the
median (50% percentile), the grey boxes show the 25–75% percentile, the
thin lines under and above the grey boxes characterise the minimal and
maximal values, the asterisks and circles represent rouge results.
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Our RT–PCR analysis of matched tissue pairs revealed strikingly
heterogeneous results for FAK mRNA levels in contrast to
FAK protein. In some cases we found in the matched pair
analysis a marked induction of FAK mRNA expression when
normalised against 18S ribosomal RNA (Figure 4A). However,
the overall statistical analysis could not confirm a general
significant induction of FAK mRNA in the neoplastic lesions
(P¼0.359).
DISCUSSION
Overexpression of tyrosine kinases is a frequently observed
phenomenon in neoplastic cells. The central role of pp125FAK in
signal transduction with potential implications in cell adhesion
and migration suggests a pivotal role for this protein in solid
tumours. Two just recently published studies found a strong
correlation of FAK levels to an aggressive breast cancer phenotype
esp. to grading and Her2/neu amplification (Lark et al, 2005;
Schmitz et al, 2005).
Our results with a focus on a neoplastic transition from normal
to malignant breast tissue support the hypothesis of an important
functional role for FAK in breast cancer biology. The matched pair
analysis of tissue specimen from the same patient revealed a gross
induction of FAK in the majority of cases. Our Western blot
analyses confirmed overexpression of pp125FAK functional
protein in breast cancer tissue compared to matched normal
controls. Low levels of pp125FAK protein were measured in
physiological breast tissue, which is in accordance to experiments
by Owens et al (1995), who found an elevated pp125FAK
expression in 22 of 25 invasive and metastatic breast tumours
compared to normal tissue. While speculating on possible reasons
for these high levels, it should be considered that pp125FAK was
shown to be an important survival signal for the anchorage-
dependent growth of cells (Wang et al, 2000), and inhibition of
pp125FAK resulted in consecutive cell death (Hungerford et al,
1996; Xu et al, 1996; Hauck et al, 2001; Golubovskaya et al, 2002).
Our RT–PCR analysis revealed only slightly and statistically not
significantly elevated FAK mRNA levels. This compromises the
earlier postulated hypothesis of an upregulation of FAK mRNA
and protein expression in breast cancer due to an increased copy
number of the fak gene on chromosome 8q (Agochiya et al, 1999).
The mRNA data of our study suggest that the protein induction is
not based on primary transcriptional effects but most likely due to
post-transcriptional or post-translational processing.
There are only few reports linking pp125FAK to breast cancer
tumorigenesis (Glukhova et al, 1995; Cance et al, 2000; Golubovs-
kaya et al, 2002; Oktay et al, 2003). Two comparative studies
demonstrated an upregulation of pp125FAK expression in the
transformational process from physiological tissue, via DCIS into
invasive cancer (Cance et al, 2000; Oktay et al, 2003) using
Northern or Western blotting techniques or immunohistochem-
istry. Cance et al (2000) found a moderate to strong expression in
14 out of 18 tumour samples and described a wide variability in the
percentage of stained tumour cells ranging from 5 to 100%.
Furthermore, the examined breast cancer specimens represented a
variety of cell types, including pure invasive ductal, mixed ductal
Table 2 Score distribution of FAK protein expression in breast tissue
Normal tissue Tumour tissue
Score n % n %
0 2 3.6 0 0
1 30 54.5 7 12.7
2 18 32.7 15 27.3
3 4 7.3 16 29.1
4 0 0 10 18.2
5 1 1.8 7 12.7
Total 55 100.0 55 100.0
Western blot score of pp125 FAK protein expression ranged from 0 to +5.
Figure 3 Induction of pp125 FAK expression in malignant vs normal
breast tissue. Immunohistochemical analysis of pp125 FAK expression in a
matched pair of physiological (A) and malignant (B) breast tissue of the
same patient. While the physiological tissue reveals only a very weak to no
expression of FAK, invasive breast carcinoma cells are characterised by a
specific membranous expression of FAK (dark brown).
417 bp
305 bp
12 11 10 9 8 7 6 5 4 3 2 1 +
12 11 10 9 8 7 6 5 4 3 2 1 +
Figure 4 Induction of pp125 FAK RNA levels in malignant vs normal
breast tissue. RT–PCR analysis of pp125 FAK RNA expression in matched
pairs of normal and malignant breast tissue using FAK-specific primer
(417nbp) and for 18S ribosomal RNA as an internal control (305bp). Lane
1, tumour 1; lane 2, normal 1; lane 3, tumour 2; lane 4, normal 2; lane 5,
tumour 3; lane 6, normal 3; lane7, tumour 4; lane 8, normal 4; lane 9,
tumour 5; lane 10, normal 5; lane 11, tumour 6; lane 12, normal 6; þ,
positive control.
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interpreted pp125FAK overexpresion as an early event in
tumorigenesis observed already in the state of DCIS (Cance et al,
2000). These results were confirmed by Oktay et al (2003), who
detected FAK overexpression already in atypical ductal hyperplasia
and 100% of the examined DCIS.
However, the significance of these findings remained unclear,
especially since Glukhova et al (1995) could not demonstrate a
pp125FAK overexpression in human breast cancer at all.
In our experiments we used total tumour tissue homogenates
and breast cancer samples which were not enriched as epithelium
pp125FAK from surrounding stromal contaminants must be taken
into consideration. Thus, we cannot conclude that pp125FAK is
necessarily upregulated exclusively in the epithelial fraction.
However, our immunohistochemical data confirmed a specific
FAK overexpression in tumour cells with only minor presence in
surrounding tissue. These findings support the hypothesis of a
specific upregulation in tumour cells.
The tumour biological importance of pp125 FAK overexpression
in breast cancer is still not clear. An interesting link might exist to
Her2/neu, since Vadlamudi et al (2003) suggested that HER2
signalling events influence metastasis of breast cancer cells
through a signalling pathway involving phosphorylation of
pp125FAK ´s tyrosine 861 via activation of Src. These results were
supported by the studies of Schmitz et al (2005) and Lark et al
(2005) both who found a strong correlation to the Her2/neu status
and grading. We could not confirm the Her2/neu results in our
study population but found in accordance to Schwartz and
Schmitz et al, the strong correlation of FAK expression and
tumour grading. These data support the evidence for an
association of FAK with a more aggressive tumour phenotype.
In summary, the frequent and specific upregulation of
pp125FAK in human breast cancer suggests an important
functional role in neoplastic signal transduction and represents a
potential marker for malignant transformation in breast epithe-
lium and target for therapeutic interventions.
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